# COMPARE ONE-PAGER (CROSS-INDUSTRY READY)

## HEADER
Ticker: KLBF
Company: Kalbe Farma Tbk
Sector: Healthcare
Industry: Drug Manufacturers - General
AsOf: 2025-09-12

## VALUATION
Market Cap: IDR 54.0 triliun
PER: 16.6x
PBV: 2.2x
Dividend Yield: 3.0%

## PROFITABILITY
Revenue Growth YoY: +7%
Net Profit Growth YoY: +17%
Net Margin: 10%
ROE: 13%
ROA: 11%

## BALANCE & CASH
DER: 0.2x
FCF: IDR 3.9 triliun

## SCORE (0â€“5 each; integers or 0.5 steps allowed)
ValuationScore: 3.5
ProfitabilityScore: 4
BalanceScore: 4.5
IncomeScore: 3.5

## NOTES
Highlights:
- Consistent revenue and net profit growth, driven by prescription drugs.
- Strong market share in prescription (13%) and health supplement (10%) categories.
- High and improving gross margin (41.6% in Q1 2025).

Risks:
- Regulatory risk from price caps (HET) on pharmaceuticals.
- Rising R&D and operational costs may pressure margins.

## METADATA
Source: Company filings, IDX, KLBF price data
Period: Q2 2025 YTD / FY 2024
LastUpdate: 2025-09-12